Extensive research published in “The New England Journal of Medicine” raises doubts about the effects of the “Paxlovid” pill developed by Pfizer, which is used in the home fight against Covid-19.
TESTED ON 109K PATIENTS IN ISRAEL
As part of the research, the Covid-19 pill was tested on 109 thousand patients in Israel.
Paxlovidin, when taken shortly after infection, has been shown to reduce hospitalizations by 75 percent in people aged 65 and over, which is consistent with results in the United States and other countries. However, it was noted that the pill did not show significant benefit in adults between the ages of 40 and 65.
MORE THAN 3.9 MILLION PRESCRIPTIONS WRITTEN
Earlier this summer, Pfizer announced that Paxlovid did not provide significant benefits on vaccinated and unvaccinated healthy adults. However, these results have not yet been published in a medical journal.
More than 3.9 million prescriptions have been written for the drug, taken twice a day for 5 days, since Paxlovid was approved for use in the US.